Evidence map›Paper›PMID 26514352›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2016

Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation.

Jan W Schrickel, Markus Linhart, Dietmar Bänsch, Daniel Thomas, Georg Nickenig

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05635864 (Impact of Catheter Ablation of Atrial Tachyarrhythmias on ABC Stroke and ABC Bleeding Risk Scores), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05635864 completednot on this mapstarted 2021, after this paper: background citation

Impact of Catheter Ablation of Atrial Tachyarrhythmias on ABC Stroke and ABC Bleeding Risk Scores

TypeobservationalSponsorHannover Medical SchoolRan2021 to 2025Enrolled167ConditionsAtrial Fibrillation, Atrial Flutter, Stroke, BleedingArmsCatheter ablation
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Review
  4. [Catheter ablation of atrial fibrillation : Status quo].Herzschrittmachertherapie & Elektrophysiologie · 2019
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jan W SchrickelDepartment of Medicine-Cardiology, University Hospital Bonn, Bonn, Germany. jan.schrickel@ukb.uni-bonn.de.
Markus LinhartDepartment of Medicine-Cardiology, University Hospital Bonn, Bonn, Germany.
Dietmar BänschDepartment of Medicine-Cardiology, University Hospital Bonn, Bonn, Germany.
Daniel ThomasDepartment of Medicine-Cardiology, University Hospital Bonn, Bonn, Germany.
Georg NickenigDepartment of Medicine-Cardiology, University Hospital Bonn, Bonn, Germany.
University of Rostock · DEUniversity Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral anticoagulation treatment following clinically successful catheter ablation of atrial fibrillation is controversial. Recent guidelines recommend continuation of oral anticoagulation in all patients with CHA2DS2VASc score ≥ 2 even if there is no evidence of recurrent atrial fibrillation. Due to lack of prospective data, the net clinical benefit of oral anticoagulation after successful ablation in these patients is unclear. As oral anticoagulation bears the risk of severe bleeding events, the ODIn-AF study aims to evaluate the effect of oral anticoagulation on the incidence of silent cerebral embolic events in patients with a high risk for embolic events, but free from symptomatic atrial fibrillation after successful pulmonary vein ablation.

Indexed as

Administration, OralAnticoagulantsAtrial FibrillationCatheter AblationDabigatranHemorrhageHumansIntracranial EmbolismProspective StudiesPulmonary VeinsResearch DesignAnticoagulantsDabigatranAtrial fibrillationCerebral embolismDabigatranOral anticoagulationPulmonary vein ablation

Identifiers

PMID26514352
OpenAlexW1957393263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.